贝尼地平对高血压病患者血浆降钙素基因相关肽水平的影响  

Effect of benidipine on plasma level of calcitonin gene-related peptide in essential hypertension

作　　者：靳文英[1] 孙威[1] 张永珍[1] 李海燕[1] 陈明哲[1] 郭静萱[1] 

机构地区：[1]北京大学第三医院心内科,北京100083

出　　处：《中华内科杂志》2004年第10期747-749,共3页Chinese Journal of Internal Medicine

摘　　要：目的　探讨钙离子拮抗剂贝尼地平对高血压病患者血浆降钙素基因相关肽 (CGRP)水平的影响。方法　 5 8例门诊高血压病患者接受贝尼地平 4～ 8mg/d治疗 8周 ,以 38例相匹配的健康者为对照 ,测定高血压病患者治疗前后和对照者的血浆CGRP水平。结果　高血压病患者的血浆CGRP水平较对照者明显降低 (最小值 :1 2 8比 39 95ng/L ;最大值 :4 3 72比 15 5 5 9ng/L ;P <0 0 0 1) ;高血压病患者经贝尼地平治疗 2周收缩压和舒张压明显降低 (P <0 0 5 ) ;之后维持治疗 8周血压稳定 ,血浆CGRP水平则较治疗前显著升高 (最小值 :2 84比 1 2 8ng/L ;最大值 :12 3 99比 4 3 72ng/L ;P<0 0 0 1)。结论　钙拮抗剂贝尼地平在降低血压的同时可明显升高高血压病患者血浆CGRP水平。Objective To explore the effect of benidipine, a calcium channel blocker on the plasma levels of calcitonin gene-related peptide (CGRP) in patients with essential hypertension. Methods 58 outpatients with essential hypertension were treated with benidipine 4-8 mg/day for 8 weeks. 38 matched healthy people were taken as controls. The plasma levels of CGRP were measured in all patients before and after treatment and in controls. Results The plasma levels of CGRP in hypertensive patients were significantly lower than those in controls (minimal value:1.28 vs 39.95 ng/L; maximal value: 43.72 vs 155.59 ng/L; P<0.001). In hypertensive patients, treatment with benidipine for 2 weeks markedly decreased systolic pressure and diastolic pressure and its depressor effect was maintained during the study (P< 0.05). At 8 week after treatment, the plasma leve ls of CGRP in hypertensive patients were significantly increased compared with those before treatment (minimal value: 2.84 vs 1.28 ng/L; maximal value: 123.99 vs 43.72 ng/L; P<0.001). Conclusion Benidipine, a calcium channel bolcker significantly decreases blood pressure concomitantly with an increase in the plasma levels of CGRP in the patients with essential hypertension.

关 键 词：贝尼地平 高血压病 血浆 降钙素基因相关肽 测定 

分 类 号：R544.1[医药卫生—心血管疾病] R972.4[医药卫生—内科学]